Management of life-threatening calcium channel blocker overdose with continuous veno-venous hemodiafiltration with charcoal hemoperfusion

Garg, Shubha; Goyal, Pankaj K.; Kumar, Rahul; Juneja, Deven; Bhasin, Alka; Singh, Omender

doi:10.4103/0972-5229.133939

Cited by 9 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We used HA-280 and HA-230 cartridges because we did not have access to other types like cytosorb, Jafron HA-380, and HA-330 in our country. There is a limited scienti c evidence about the application of HA-280 and HA-230 cartridges in clinical settings (24,25). Previous study in which the e cacy of HA-330 resin-directed hemoperfusion has been assessed in acute respiratory distress syndrome, some considerable treatment outcomes including improved oxygenation, reduction in lung edema and histopathological signs of acute respiratory distress syndrome, and reduced circulating and alveolar cytokine levels have been resulted; and the authors concluded that this cartridge could bene cially in uence the course of acute respiratory distress syndrome by attenuating systemic and pulmonary in ammatory cytokines (12).…”

Section: Resultsmentioning

confidence: 99%

Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)

Asgharpour

Mehdinezhad

Bayani

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Extracorporeal blood purification has been proposed as one of the therapeutic approaches in patients with coronavirus infection, because of its beneficial impact on elimination of inflammatory cytokines. Methods This controlled trial has been conducted on critically ill COVID-19 patients admitted in the state hospital affiliated to Babol University of Medical Sciences, Iran who received different antiviral and antibacterial drugs, and different modalities of respiratory treatments and did not have positive clinical improvement. No randomization and blindness was considered. All of the participants underwent three sessions of resin-directed hemoperfusion using continuous renal replacement therapy with a mode of continuous venovenous hemofiltration (CVVH). Results Five men and five women with a mean age of 57.30 ± 18.07 years have been enrolled in the study; and six of them have improved after the intervention. Peripheral capillary oxygen saturation (SpO2) changed after each session. Mean SpO2 before the three sessions of hemoperfusion was 89.60%±3.94% and increased to 92.13%±3.28% after them (p < 0.001). Serum IL-6 showed a reduction from 139.70 ± 105.62 to 72.06 ± 65.87 pg/mL (p = 0.073); and c-reactive protein increased from 136.25 ± 84.39 to 78.25 ± 38.67 mg/L (P = 0.016). Conclusions Extracorporeal hemoadsorption could improve the general condition in most of recruited patients with severe coronavirus disease; however, large prospective multicenter trials in carefully selected patients are needed to definitely evaluate the efficacy of hemoperfusion in COVID-19 patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)

Asgharpour

Mehdinezhad

Bayani

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…We used HA-280 and HA-230 cartridges because we did not have access to other types like cytosorb, Jafron HA-380, and HA-330 in our country. There is a limited scientific evidence about the application of HA-280 and HA-230 cartridges in clinical settings [ 26 , 27 ]. Previous study in which the efficacy of HA-330 resin-directed hemoperfusion has been assessed in acute respiratory distress syndrome, some considerable treatment outcomes including improved oxygenation, reduction in lung edema and histopathological signs of acute respiratory distress syndrome, and reduced circulating and alveolar cytokine levels have been resulted; and the authors concluded that this cartridge could beneficially influence the course of acute respiratory distress syndrome by attenuating systemic and pulmonary inflammatory cytokines [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)

et al. 2020

View full text Add to dashboard Cite

Background Extracorporeal blood purification has been proposed as one of the therapeutic approaches in patients with coronavirus infection, because of its beneficial impact on elimination of inflammatory cytokines. Methods This controlled trial has been conducted on critically ill COVID-19 patients admitted in the state hospital affiliated to Babol University of Medical Sciences, Iran who received different antiviral and antibacterial drugs, and different modalities of respiratory treatments and did not have positive clinical improvement. No randomization and blindness was considered. All of the participants underwent three sessions of resin-directed hemoperfusion using continuous renal replacement therapy with a mode of continuous venovenous hemofiltration (CVVH). Results Five men and five women with a mean age of 57.30 ± 18.07 years have been enrolled in the study; and six of them have improved after the intervention. Peripheral capillary oxygen saturation (SpO2) changed after each session. Mean SpO2 before the three sessions of hemoperfusion was 89.60% ± 3.94% and increased to 92.13% ± 3.28% after them ( p < 0.001). Serum IL-6 showed a reduction from 139.70 ± 105.62 to 72.06 ± 65.87 pg/mL ( p = 0.073); and c-reactive protein decreased from 136.25 ± 84.39 to 78.25 ± 38.67 mg/L ( P = 0.016). Conclusions Extracorporeal hemoadsorption could improve the general condition in most of recruited patients with severe coronavirus disease; however, large prospective multicenter trials in carefully selected patients are needed to definitely evaluate the efficacy of hemoperfusion in COVID-19 patients. Trial registration The research protocol has been registered in the website of Iranian Registry of Clinical Trials with the reference number IRCT20150704023055N2 .

show abstract

“…We used HA-280 and HA-230 cartridges because we did not have access to other types like cytosorb, Jafron HA-380, and HA-330 in our country. There is a limited scienti c evidence about the application of HA-280 and HA-230 cartridges in clinical settings (26,27). Previous study in which the e cacy of HA-330 resin-directed hemoperfusion has been assessed in acute respiratory distress syndrome, some considerable treatment outcomes including improved oxygenation, reduction in lung edema and histopathological signs of acute respiratory distress syndrome, and reduced circulating and alveolar cytokine levels have been resulted; and the authors concluded that this cartridge could bene cially in uence the course of acute respiratory distress syndrome by attenuating systemic and pulmonary in ammatory cytokines (12).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)

Asgharpour

Mehdinezhad

Bayani

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Extracorporeal blood purification has been proposed as one of the therapeutic approaches in patients with coronavirus infection, because of its beneficial impact on elimination of inflammatory cytokines. Methods This controlled trial has been conducted on critically ill COVID-19 patients admitted in the state hospital affiliated to Babol University of Medical Sciences, Iran who received different antiviral and antibacterial drugs, and different modalities of respiratory treatments and did not have positive clinical improvement. No randomization and blindness was considered. All of the participants underwent three sessions of resin-directed hemoperfusion using continuous renal replacement therapy with a mode of continuous venovenous hemofiltration (CVVH). Results Five men and five women with a mean age of 57.30±18.07 years have been enrolled in the study; and six of them have improved after the intervention. Peripheral capillary oxygen saturation (SpO2) changed after each session. Mean SpO2 before the three sessions of hemoperfusion was 89.60%±3.94% and increased to 92.13%±3.28% after them (p<0.001). Serum IL-6 showed a reduction from 139.70±105.62 to 72.06±65.87 pg/mL (p=0.073); and c-reactive protein increased from 136.25±84.39 to 78.25±38.67 mg/L (P=0.016). Conclusions Extracorporeal hemoadsorption could improve the general condition in most of recruited patients with severe coronavirus disease; however, large prospective multicenter trials in carefully selected patients are needed to definitely evaluate the efficacy of hemoperfusion in COVID-19 patients.

show abstract

Management of life-threatening calcium channel blocker overdose with continuous veno-venous hemodiafiltration with charcoal hemoperfusion

Cited by 9 publications

References 11 publications

Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)

Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)

Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)

Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)

Contact Info

Product

Resources

About